文献速递皮肤肿瘤

皮肤T细胞淋巴瘤与淋巴瘤、黑色素瘤、肺癌及膀胱癌风险增加相关

Cutaneous T-cell lymphoma is associated with increased risk of lymphoma, melanoma, lung cancer, and bladder cancer.
PubMed 文献 · J Am Acad Dermatol · 2020-08-18

该系统综述与荟萃分析纳入1950至2019年发表的10项合格研究(12个患者队列),发现5.9%至16.8%的皮肤T细胞淋巴瘤(CTCL)患者发生第二恶性肿瘤。荟萃分析显示全部恶性肿瘤的标准化发病比为2.18(95%CI 1.43-2.93),霍奇金淋巴瘤、非霍奇金淋巴瘤、肺癌、膀胱癌和黑色素瘤的风险均升高。

要点

  • CTCL患者发生第二恶性肿瘤的风险显著增加,全部恶性肿瘤标准化发病比为2.18。
  • 霍奇金淋巴瘤风险最高(标准化发病比15.25),其次为非霍奇金淋巴瘤和黑色素瘤。
  • 第二恶性肿瘤多发生于CTCL诊断后2.1至5.4年,男性占优势。

核心结论

  • CTCL患者发生第二恶性肿瘤的风险增加,尤其是霍奇金淋巴瘤、非霍奇金淋巴瘤、肺癌、膀胱癌和黑色素瘤。

研究设计与样本

  • 系统综述与荟萃分析,纳入1950至2019年发表的10项合格研究,共12个患者队列。

主要发现

  • 5.9%至16.8%的CTCL患者发生第二恶性肿瘤,所有研究均显示男性占优势。
  • 研究间平均年龄范围为44.6至68.0岁。
  • CTCL诊断至第二恶性肿瘤的时间范围为2.1至5.4年(均值3.29年,95%CI 2.69-5.15)。
  • 全部恶性肿瘤标准化发病比为2.18(95%CI 1.43-2.93)。
  • 霍奇金淋巴瘤标准化发病比为15.25(95%CI 7.70-22.79),非霍奇金淋巴瘤为4.96(95%CI 3.58-6.33),肺癌为1.69(95%CI 1.18-2.21),膀胱癌为1.72(95%CI 1.18-2.21),黑色素瘤为3.09(95%CI 1.77-6.43)。

临床怎么用

  • 研究结果提示CTCL患者为恶性肿瘤高风险人群,早期发现可能降低第二恶性肿瘤的疾病负担。
  • 该证据为开展前瞻性筛查研究提供了强有力依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with cutaneous T-cell lymphoma (CTCL) are at a higher risk of developing second malignancies. However, rates of incidence vary significantly across studies. METHODS: A systematic review and meta-analysis of articles published between 1950 and 2019 was performed to evaluate the risk of second malignancies in patients with CTCL. RESULTS: We identified 10 eligible studies, including 12 patient cohorts, with 5.9% to 16.8% of patients developing second malignancies. All studies showed a male predominance for patients developing second malignancies. The mean age across the studies ranged from 44.6 to 68.0 years. The time between the diagnosis of CTCL and second malignancy ranged from 2.1 to 5.4 years (mean, 3.29 y; 95% confidence interval [CI], 2.69-5.15). Meta-analysis showed a standardized incidence ratio of 2.18 (95% CI, 1.43-2.93) for all malignancies. The standardized incidence ratios were 15.25 (95% CI, 7.70-22.79) for Hodgkin lymphoma, 4.96 (95% CI, 3.58-6.33) for non-Hodgkin lymphoma, 1.69 (95% CI, 1.18-2.21) for lung cancer, 1.72 (95% CI, 1.18-2.21) for bladder cancer, and 3.09 (95% CI, 1.77-6.43) for melanoma. CONCLUSIONS: We find that patients with CTCL are at increased risk of second malignancies, especially Hodgkin and non-Hodgkin lymphoma, lung cancer, bladder cancer, and melanoma. These findings provide evidence of a population at increased risk of malignancy. Early detection may decrease the morbidity burden of second malignancies, thus providing a strong rationale for prospective screening studies.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Goyal A, O'Leary D, Goyal K, et al. Cutaneous T-cell lymphoma is associated with increased risk of lymphoma, melanoma, lung cancer, and bladder cancer. J Am Acad Dermatol. 2020. PMID: 32822803. doi:10.1016/j.jaad.2020.06.1033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。